How to Map ALPL Inheritance Across Three Generations: A Geneticist’s Guide

Understanding how variants in the ALPL gene cause hypophosphatasia (HPP) can help families make informed decisions about testing, treatment and monitoring. This guide walks you through mapping ALPL inheritance across three generations, with clear steps and practical tips.

---

1. Know the Basics of Hypophosphatasia and ALPL

• Hypophosphatasia (HPP) is a rare metabolic bone disease caused by mutations in the ALPL gene.
• ALPL encodes tissue-nonspecific alkaline phosphatase (TNSALP); abnormal TNSALP activity leads to defective bone mineralization.
• HPP can present at any age—from severe perinatal forms to mild adult or odontohypophosphatasia.
• Inheritance can be autosomal recessive (most common in severe cases) or autosomal dominant (often milder).

---

2. Assemble a Three-Generation Pedigree

A pedigree chart visualizes who in the family is affected, unaffected or a carrier.

1. Define Generations

   • Generation I (Grandparents)
   • Generation II (Parents and their siblings)
   • Generation III (Children and cousins)

2. Gather Key Information

   • Full names, current ages (or age at death)
   • Health history: fractures, premature tooth loss, bone pain, muscle weakness
   • Any formal HPP diagnoses or genetic test results

3. Use Standard Symbols

   • Squares = males; circles = females
   • Filled shapes = affected individuals
   • Half-filled = carriers (if known)
   • Diagonal slash = deceased

4. Document Relationships

   • Marriages (horizontal line), sibships (bracket), and children (vertical line).
   • Note consanguinity if present (double line).

---

3. Identify Patterns of Inheritance

Autosomal Recessive HPP

• Requires two mutated ALPL alleles for symptoms.
• Parents are often carriers (one mutated allele) without symptoms.
• Recurrence risk for each child of carrier parents:
  • 25% affected (two mutated alleles)
  • 50% carriers
  • 25% unaffected

Autosomal Dominant HPP

• One mutated ALPL allele can cause disease (often milder).
• An affected parent has a 50% chance of passing the variant to each child.
• Variable expressivity means severity may differ among family members.

---

4. Collect Clinical and Laboratory Data

1. Clinical Evaluation

   • Bone pain, fractures, poor growth (children).
   • Muscle weakness, dental issues, early tooth loss.

2. Biochemical Testing

   • Low serum alkaline phosphatase (ALP) activity is a hallmark.
   • Elevated substrates: pyridoxal-5′-phosphate (PLP), phosphoethanolamine (PEA).

3. Symptom Tracking

   • Encourage at-risk relatives to note any signs over time.
   • Suggest a free, online symptom check, using the doctor approved Ubie Symptom Checker to flag potential issues early.

---

5. Choose the Right Genetic Test

• Targeted ALPL Mutation Analysis

  • Ideal when a family’s disease-causing variant is already known.
  • Quick and cost-effective for relatives.

• Comprehensive Gene Panel for Bone Disorders

  • Includes ALPL plus other genes related to bone mineralization.
  • Useful if clinical presentation is atypical.

• Whole Exome Sequencing (WES)

  • Broader approach when phenotype is unclear or previous tests are negative.
  • Longer turnaround and higher cost.

• Copy Number Variant (CNV) Analysis

  • Detects large deletions or duplications in ALPL not visible on sequencing.

---

6. Map Test Results onto the Pedigree

1. Positive for Pathogenic ALPL Variant

   • Shade symbol completely.
   • Note zygosity: heterozygous (one copy) vs homozygous/compound heterozygous (two copies).

2. Carrier (Heterozygous in Recessive Families)

   • Use a half-filled symbol.
   • Emphasize that carriers rarely show severe symptoms but should be monitored.

3. Negative for Family Variant

   • Leave symbol unshaded.
   • Counsel individuals that their risk is similar to the general population.

4. Variant of Uncertain Significance (VUS)

   • Mark with a question mark.
   • Recommend periodic re-evaluation as databases are updated.

---

7. Interpret Risks and Recurrence

• Couples Planning a Pregnancy

  • If both are carriers (recessive HPP), each child has a 25% chance of HPP.
  • Offer options like prenatal testing or preimplantation genetic diagnosis (PGD).

• Affected Individuals

  • With autosomal dominant HPP, 50% risk per pregnancy.
  • Discuss variability: a parent’s mild symptoms don’t guarantee mild disease in offspring.

• At-Risk Relatives

  • Unaffected siblings of an affected child have a 2/3 chance of being carriers in recessive families.
  • Offer cascade testing: testing relatives based on known family variants.

---

8. Communicate Clearly with the Family

• Use plain language to explain terms like “allele,” “carrier,” “compound heterozygote.”
• Discuss psychosocial aspects—anxiety, family planning—and refer to genetic counseling for support.
• Emphasize that knowing one’s genetic status can guide surveillance (bone density scans, dental checkups) and treatment (enzyme replacement therapy).

---

9. Update and Review Regularly

• Pedigrees are living documents.
• Re-evaluate every few years or when new family members, diagnoses or test results arise.
• Reclassify VUS when laboratory evidence or databases have evolved.

---

10. Next Steps and Resources

• Arrange a genetic counseling session for detailed risk assessment.
• Coordinate with an endocrinologist, orthopedic specialist or metabolic bone clinic.
• Consider joining a patient registry for hypophosphatasia to stay informed about clinical trials.
• Maintain open communication: encourage family members to report new symptoms or medical changes promptly.

---

Important: This guide is for informational purposes only. It does not replace professional medical advice. Always speak to a doctor about anything that could be life-threatening or serious. If you suspect you or a family member has hypophosphatasia or carry an ALPL variant, consult a qualified healthcare provider for personalized evaluation and management.